Author Archives: admin


South Setauket native announces $100G donation to Stony Brook University Hospital – GreaterMoriches

Ward Melville High Schoolalum Dave Wolmetz was once again surrounded by his heroes.

Last Thursday, Wolmetz who co-owns Urban Air Lake Grove with his partner Keith Handler invited the people that saved his life from Stony Brook University Cancer Center to his family entertainment facility. There, he presented the staff with a check worth $100,000.

Im inspired by the groundbreaking research at the Stony Brook University Cancer Center, said Wolmetz, who began treatment of Acute lymphocytic leukemia (ALL) in 2018 at Stony Brook University Hospital.

The South Setauket native underwent total body radiation and chemotherapy treatment at Stony Brooks Cancer Center and is currently in the management phase of his treatment.

Im grateful for the stem cell transplant and excellent care I have received at the facility, he said. The cancer center is a well-established resource and essential to the community to focus on important cancer problems.

The donation money hails from the Why Not Us Foundation, a nonprofit that is dedicated to creating real and lasting change in the world by motivating, empowering and preparing todays youth to be tomorrows leaders.

The funds will benefit Stony Brooks CAR T-cell therapy program, which supports Stony Brook scientists working on developing personalized cell therapy to treat blood cancers, such as leukemia.

The donation ceremony was timely, as it was the one-year anniversary of Wolmetzs stem cell transplant at Stony Brook.

With the incredible generosity, we will be able to improve cancer care for Long Islanders and generate other CARs directed toward other major blood cancers, such as leukemia and multiple myeloma, said Dr. Huda Salman, a hematologist at Stony Brook. Dave Wolmetz (blue) with members of the Stony Brook University Hospital (courtesy)

Top: Urban Air Lake Grove founders Dave Wolmetz and Keith Handler presenting the $100,000 check to Stony Brook University Hospital.

Follow this link:
South Setauket native announces $100G donation to Stony Brook University Hospital - GreaterMoriches

Cell Therapy Market 2020 Insights on Growth Drivers, Dynamics, Key Players, Investment Analysis, Business Opportunities and Future Trends – 3rd Watch…

The study report on Global Cell Therapy Market delivers the market revenue predictions for each geographical region. In addition, the Cell Therapy report also offers market insight on growth opportunities, disruptive technologies on the basis of innovative business models, several value-added services, and the competitive background of the market which can increase the market growth. Likewise, the report also contains top predictions of the global Cell Therapy market over the forecast period. The report is designed with the forecast period to anticipate the market size of Cell Therapy industry.

Get Sample PDF Report @ https://www.adroitmarketresearch.com/contacts/request-sample/611

The most commonly used process of cell therapy aims to use healthy cells from a donor (Allogeneic) which is compatible or autogenic that is from the patient itself along with their alteration to increase their therapeutic ability. There are various complex steps involved in the process like genetic screening of cell, cell harvesting and reinfusion into the patients body. All these steps are complex and important and have therapeutic result on the patient. These advanced usage of cell therapy will result in growth of the cell therapy market size during the forecast period.

Cell therapy market trends indicate growth owing to the various regulations being approved by the government in the desire to provide quick relief to the patients. Furthermore, many healthcare industries are working in collaboration with the government to identify the various processes to ways to improve cell therapy. Furthermore, the cell therapy market size is also influenced by the commercialization of stem cells treatments.

Browse Complete Report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

The Stem cell therapy segment dominates the types of cell therapy and is said to have the maximum success rate. It has a special feature that it differentiates into any category of cell, at the same time ensuring the individual identity is intact. Industry experts state that the stem cell would revolutionize regenerative medicine, owing to its extensive use in treatment of fatal disease like neurodegenerative, cardiovascular and cancer. The growth of cell therapy market size is also factored to the increased research and development about the same. However, at the same time the huge cost involved in the various processes involved might be hinder the market growth.

The cell therapy market size is segmented on various categories like Clinical-use, Research and Therapy type and region. On the basis of region, North America is projected to contribute the maximum share to the market owing to increased development.

Key players in the market are JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Segmentation:

The various segments of cell therapy market size are:

By Use & Type Outlook

By Cell Therapy Type

By Therapeutic Area

By Therapy Type

By Region

Buy This Report @ https://www.adroitmarketresearch.com/researchreport/purchase/611

About Adroit Market Research:

Adroit Market Research provide quantified B2B research on numerous opportunistic markets, and offer customized research reports, consulting services, and syndicate research reports. We assist our clients to strategize business decisions and attain sustainable growth in their respective domain. Additionally, we support them with their revenue planning, marketing strategies, and assist them to make decisions before the competition so that they remain ahead of the curve.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 (214) 884-6068 / +91 9665341414

Read the original:
Cell Therapy Market 2020 Insights on Growth Drivers, Dynamics, Key Players, Investment Analysis, Business Opportunities and Future Trends - 3rd Watch...

Gilead to Acquire Forty Seven for $4.9 Billion – PharmiWeb.com

Gilead Gains Forty Sevens Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma

Transaction Supports Gileads Strategic Focus in Oncology and Gives Access to Potential New First-in-Class Program and Innovative Pipeline

FOSTER CITY, Calif.&MENLO PARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc.(Nasdaq: GILD) andForty Seven, Inc.(Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for$95.50per share in cash. The transaction, which values Forty Seven at approximately$4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions.

This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20200302005443/en/

Through the addition of Forty Sevens investigational lead product candidate, magrolimab, the acquisition will strengthen Gileads immuno-oncology research and development portfolio. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). The investigational therapy targets CD47, a do not eat me signal that allows cancer cells to avoid destruction thereby permitting the patients own innate immune system to engulf and eradicate those cancer cells. Forty Seven presented promising results of a Phase 1b study of magrolimab in patients with MDS and AML at theAmerican Society of Hematologymeeting inDecember 2019. Magrolimab has the potential to be a first-in-class therapy.

This agreement builds on Gileads presence in immuno-oncology and adds significant potential to our clinical pipeline, said Daniel ODay, Chairman and Chief Executive Officer ofGilead Sciences. Magrolimab complements our existing work in hematology, adding a non-cell therapy program that complements Kites pipeline of cell therapies for hematological cancers. With a profile that lends itself to combination therapies, magrolimab could potentially have transformative benefits for a range of tumor types. We are looking forward to working with the highly experienced team at Forty Seven to help patients with some of the most challenging forms of cancer.

This is an exciting day for patients who may one day benefit from future anti-CD47 therapies and other immuno-oncology treatments based on our research and an exciting time for Forty Seven as this allows us to achieve our vision of helping patients defeat their cancer, commentedMark McCamish, MD, PhD, President and Chief Executive Officer of Forty Seven. We are pleased to join Gilead and believe that by combining our scientific expertise with Gileads strength in developing treatments that modify the immune system, we will be able to more rapidly advance our therapies.

Magrolimab

Forty Seven is initially studying magrolimab in patients with MDS and AML. Additional studies are ongoing in non-Hodgkin lymphoma (NHL) and solid tumors. Magrolimab has been granted Fast Track designation by theU.S. Food and Drug Administration(FDA) for the treatment of MDS and AML, and for the treatment of relapsed or refractory DLBCL and follicular lymphoma, two forms of B-cell NHL. Magrolimab has also been granted Orphan Drug designation by the FDA for the treatment of MDS and AML and by theEuropean Medicines Agencyfor the treatment of AML.

More than 400 patients have received the compound to date through clinical trials.

Ongoing Phase 1b Clinical Trial

InDecember 2019, Forty Seven presented promising results of a Phase 1b trial evaluating magrolimab in combination with azacitidine in untreated patients with higher risk MDS and untreated patients with AML, who are ineligible for induction chemotherapy. This has led to the initiation of a potential registrational cohort in MDS. All patients received a 1 mg/kg priming dose of magrolimab, coupled with intrapatient dose escalation to mitigate on-target anemia. Patients were then treated with full doses of azacitidine and magrolimab maintenance doses of 30 mg/kg weekly.

As of the data cutoff ofNovember 18, 2019, 62 patients had been treated with the combination in the Phase 1b portion of the trial, including 35 patients with MDS and 27 patients with AML.

Clinical Activity Data

As of the data cutoff, 46 patients were evaluable for response assessment, including 24 patients with untreated higher-risk MDS and 22 patients with untreated AML, who were ineligible for induction chemotherapy.

Safety Data

As of the data cutoff, the combination of magrolimab and azacitidine was well-tolerated, with no evidence of increased toxicities compared to azacitidine alone. Adverse events (AEs) were consistent with prior clinical experience. No deaths were observed in the first 60 days on combination treatment and only one patient out of 62 (1.6 percent) discontinued treatment due to a treatment-related AE.

Additional Programs

Beyond magrolimab, Forty Seven is preparing to advance two additional investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP antibody, is being developed for the treatment of cancer, as well as certain non-oncology settings, including transplantation conditioning.

Terms of the Transaction

Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Forty Sevens common stock at a price of$95.50per share in cash. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer.

Consummation of the tender offer is subject to a minimum tender of at least a majority of outstanding Forty Seven shares plus Forty Seven shares underlying vested options, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

Gilead plans to pay all cash consideration for the transaction. The tender offer is not subject to a financing condition.

Citi and J.P. Morgan are acting as joint financial advisors to Gilead.Centerview Partners LLCis acting as the exclusive financial advisor to Forty Seven.Skadden, Arps, Slate, Meagher & Flom LLPis serving as legal counsel toGileadandCooley LLPis serving as legal counsel to Forty Seven.

Conference Call

At8:00 a.m. Eastern Timetoday, Gilead's management will host a conference call and a simultaneous webcast to discuss the transaction. A live webcast of the call can be accessed at Gileads Investors page athttp://investors.gilead.com. Please connect to the website at least 15 minutes prior to the start of the call to allow adequate time for any software download that may be required. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8479332 to access the call.

Telephone replay will be available approximately two hours after the call through8:30 a.m. Eastern Time,March 4, 2020. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 8479332. The webcast will be archived onwww.gilead.comfor one year.

AboutGilead Sciences

Gilead Sciences, Inc.is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters inFoster City, California. For more information onGilead Sciences, please visit the companys website atwww.gilead.com.

About Forty Seven

Forty Seven, Inc.is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed fromStanford University. Forty Sevens lead program, magrolimab, is a monoclonal antibody against the CD47 receptor, a dont eat me signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. For more information on Forty Seven, please visit the companys website atwww.fortyseveninc.com.

Original post:
Gilead to Acquire Forty Seven for $4.9 Billion - PharmiWeb.com

Adult Stem Cells: Market 2020 New Innovative Solutions to Boost Global Growth with New Technology, Key Business Strategies, Trend and Forecasts 2024 -…

The Global Adult Stem Cells Market Report Provides A Detailed Analysis of The Current Dynamics of The Market with An Extensive Focus on Secondary Research. It Also Studies the Current Situation of The Market Estimate, Share, Demand, Development Patterns, And Forecast in The Coming Years. The Report Likewise Offers A Total Adult Stem Cells Analysis of Things to Come Patterns and Improvements. It Likewise Examines at The Job of The Main Market Players Engaged with The Business Including Their Adult Stem Cells Corporate Review, Financial Summary and SWOT Analysis.

This Adult Stem Cells Market Report That Is Imagines That the Length of This Market Will Develop during The Time System While the Compound Annual Growth Rate (CAGR) Development. The Adult Stem Cells Business Report Point Would Be the Economic Situations and Relating Orders and Takes the Market Players in Driving Fields Over the World.

GlobalstemJuventas Therapeutics Inc.Epistem Ltd.Hybrid Organ GmbhCellerix SaMesoblast Ltd.Intellicell Biosciences Inc.NeuralstemCelyadCapricor Inc.ClontechCellerant Therapeutics Inc.Cellular Dynamics InternationalBiotime Inc.Beike Biotechnology Co. Ltd.Brainstorm Cell Therapeutics Inc.NeurogenerationInternational Stem Cell Corp.Gamida Cell Ltd.Caladrius Biosciences Inc.Cytori Therapeutics Inc.

Most important types of Adult Stem Cells products covered in this report are:Epithelial stem cellsHematopoietic stem cells

Most widely used downstream fields of Adult Stem Cells market covered in this report are:Neurodegenerative diseasesHeart diseaseBone diseaseOthers

Which prime data figures are included in the Adult Stem Cells market report?

What are the crucial aspects incorporated in the Adult Stem Cells market report?

Who all can be benefitted out of this Adult Stem Cells market report?

Research Goals:

The Report on Global Adult Stem Cells Market Studies the Strategy Pattern Adopted by Prominent International Players. Additionally, The Report Also Evaluates the Market Size in Terms of Revenue (USD MN) For the Forecast Period. All Data and Figures Involving Percentage Shares Splits, And Breakdowns Are Determined Using Secondary Sources and Verified Through Primary Sources.

Contact Us:Web: http://www.qurateresearch.comE-mail: [emailprotected]Ph: US +13393375221, IN +919881074592

Original post:
Adult Stem Cells: Market 2020 New Innovative Solutions to Boost Global Growth with New Technology, Key Business Strategies, Trend and Forecasts 2024 -...

Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes – Cambridge Independent

It is the worlds biggest killer and yet we dont fully understand the leading cause behind it.

Cardiovascular diseases claimed an estimated 17.9 million lives in 2016 31 per cent of all deaths around the globe.

And 85 per cent of these were due to heart attacks and stroke, most commonly caused by a blockage of the arteries known as atherosclerosis.

Now an international team led by a Cambridge professor of cardiovascular medicine is competing for a 30million prize from the British Heart Foundation to unravel its secrets.

If they beat the other three shortlisted teams in the charitys Big Beat Challenge, they will create the worlds first 3D map of atherosclerosis at single cell resolution, giving unparalleled insight into this hardening or blocking of the arteries.

Prof Ziad Mallat, of the Department of Medicine at the University of Cambridge, tells the Cambridge Independent:We are excited about the prospect of this. We hope we have assembled the right team.

Atherosclerosis is very debilitating. If it happens in the arteries that supply the brain, it causes stroke. If it happens in the arteries supplying the heart, it causes heart attacks.

It is really common across the world. Every five minutes in the UK there is one heart attack and one stroke.

Why is this having such a huge impact on the quality of life of people? We believe something is not being treated or understood.

Clinicians currently treat the risk factors for the disease, which include high blood cholesterol, high blood pressure and diabetes.

What we dont do is really treat what causes the disease, which is the malfunctioning of the immune system, says Prof Mallat.

When you have high blood pressure or cholesterol, this injures the arteries. Initially, the immune system sends immune cells to the injured vessel to try to heal the artery.

However, what we know is that most of the time the immune system doesnt operate properly and this prevents the healing, and so the disease progresses.

We have good understanding of how this happens in pre-clinical models, like mouse models, but very limited understanding of how it happens in humans.

We think this is what is preventing doctors and scientists from finding a treatment that would transform the way patients are treated.

Through their iMap, as they are calling it, Prof Mallat and the team of global experts he has assembled want to understand what is happening in the accumulations, known as plaques, that block the arteries and affect blood flow to the heart and other parts of the body. The plaques can be made up of fat, cholesterol, calcium and other substances.

These plaques obstruct the lumen [the interior space in the artery] and even burst into the lumen, leading to clot formation, which obstructs the blood flow. This causes the heart attacks and strokes, says Prof Mallat.

Our idea is to build the first 3D map of these fatty plaques, at

. We would like to know what each immune cell and each cell in the vessel wall is doing. What is its genetic make-up? What is its protein make-up? What is the fuel that it is using? Why, when the immune cell comes along to do a good job, does it stop doing it?

We want to interrogate each cell and work out how it is interacting and communicating with other cells.

Only with this 3D map of the plaques will we be able to understand what is happening inside. Once we have done this, we will be able to harness this knowledge to find new protective methodologies and therapies.

These therapies could harness the immune system, which raises the possibility of vaccinating against atherosclerosis.

If we understand how the immune cells react, we can use the information to re-educate them with vaccination, suggests Prof Mallat. If they are overreacting to fat components or protein components, we can educate them to make them do the right job when they see this in the arteries, to reduce the inflammation and limit the development of the disease.

The scale of this challenge, however, is vast and requires a multi-disciplinary approach.

It needs a lot of different expertise around the world, says Prof Mallat. You need good cardiologists, good molecular biologists, immunologists, mathematicians and computer scientists because the information will be huge and needs to be integrated together. You need people who know a lot about genomics, lipidomics and proteomics, so we have gathered world-leading experts in each of these areas to come together and look at this problem from every angle possible.

Among those helping Prof Mallat is Sarah Teichmann, from the Wellcome Sanger Institute at Hinxton, who is the co-founder of the global consortium working on the Human Cell Atlas a hugely ambitious and important project creating comprehensive reference maps of all human cells in the human body.

They are looking at the make-up of healthy organs, notes Prof Mallat. Some of the investigators are mapping some of the arteries and are looking at vascular cells like endothelial cells. It is intriguing but nobody else is looking at other cells in the artery. We are looking at both the healthy arteries and the diseased arteries. It is building on the work of the Human Cell Atlas.

Also on the team are experts from Imperial College London, Germany, France, Spain, the La Jolla Institute of Immunology in San Diego and from Icahn School of Medicine at Mount Sinai in New York.

Key to their work is the need for data and samples, and the group has multiple sources available.

We have organ donors from the Cambridge bio-repository and the clinical school at Mount Sinai, so we have access to healthy and diseased arteries from the same individuals.

We have access to blood from these individuals and to immune cells from other parts of the body, so we can compare what the immune cells are doing in different compartments.

The other source is from a cohort of thousands of individuals, through a collaboration with Professor Valentin Fuster in Madrid, who have been followed for more than 10 years, and they will be followed for another 10 years.

We have blood samples and microbiota from them. We also have access to imaging of their arteries. They are followed for cardiovascular outcomes, so if someone has a heart attack or stroke, it is documented.

We will be able to look at the ageing of the immune system in these individuals and how this correlates to changes in their arteries and the occurrence of disease.

All of this is being done at very high resolution, which has not been done before. Integrating the information from the genes, the proteins, the lipids and so on, to have a broad view, has never been possible.

There are parallels with the work being carried out at Cancer Research UK Cambridge Institute under Prof Greg Hannon, where the first virtual 3D tumour is being created using a multi-disciplinary team.

We are discussing with him how we can integrate some of the technologies he is developing. It will be fantastic to collaborate with him on this, says Prof Mallat.

What is known already is that our arteries are sensitive to changes in blood flow.

Even subtle perturbations in the micro-environment are sensed by the arteries and can be considered as a danger, explains Prof Mallat.

When it interprets this as a danger, it sends signals to the immune system to react. I would say this is happening almost continuously, and is aggravated of course when you have additional stimuli like high blood cholesterol or exposure to smoke.

While the use of imaging and monitoring of biomarkers is helping us diagnose atherosclerosis earlier, Prof Mallat describes this as not optimal, because we dont understand the disease in a comprehensive manner. A 3D map would aid diagnosis, prediction and prevention of disease, as well as opening up new therapeutic avenues.

Nobody knew 10 or 15 years ago that the immune system could play such a huge role in cancer, Prof Mallat points out. Now cancer immunotherapy is advancing enormously. We are convinced that atherosclerosis is highly motivated by the immune system but no-one is targeting the immune system to treat it. Thats why we want to understand it and we think this could really induce a revolution in our understanding and how we treat it.

Cambridge Cardiovascular to host events at Cambridge Science Festival

Visitors to Cambridge Science Festival will have a chance to find out more about the iMap project and the work of cardiovascular researchers.

Cambridge Cardiovascular, an umbrella group for the field, is involved in organising activities once again at this years festival, which runs from March 9 to 22.

At 6-7pm on Wednesday, March 18 at the Mill Lane lecture rooms in Cambridge, a talk titled More than a blocked pipe: The hardening of the arteries and their role in stroke and heart attacks will be delivered by Dr Nick Evans, of the Department of Medicine, and Prof Melinda Duer, of the Department of Chemistry.

At 6-7pm on Friday, March 20, also at Mill Lane lecture rooms, Dr Sanjay Sinha, of Cambridge Stem Cell Instituteand the Department of Medicine will discuss Mending broken hearts: stem cells for heart disease.

Then, from 11am to 4pm on Sunday, March 22, A View of the Heart will be on offer at the Cambridge Academy for Science and Technology, in Long Road, where cardiovascular scientists will help you explore the organ and visualise heartbeats.

Book at sciencefestival.cam.ac.uk.

The Big Beat Challenge

The British Heart Foundations 30million Big Beat Challenge is designed as the charitys moon-shot to propel our understanding of cardiovascular disease into a new era.

Some 75 applications were received from 40 countries following its launch in August 2018, and these have been whittled down to four, including the one led by Prof Mallat to map and treat atherosclerosis. The other ideas are:

Hybrid heart

Led by Jolanda Kluin, professor of translational cardiothoracic surgery at the University of Amsterdam in the Netherlands, this team plans to create a solution for heart failure by developing a soft robotic heart. They intend to design, build, test and implant a hybrid heart that consists of a soft robotic shell forming the soft artificial muscles and sensors to enable natural motion, and a tissue-engineered lining to make sure all the surfaces in contact with blood are safe. With wireless energy transfer, the vision is that this could replace the need for human heart transplantation.

Echoes

Led by Professor Frank Rademakers, chief medical technology officer at University Hospitals Leuven, Belgium, this team would develop wearable technology that can be used in daily life to capture more data than ever before. This information ranging from symptoms and physical activity to heart function and air quality could be used alongside genetic and healthcare data to transform diagnosis, monitoring and treatment of heart and circulatory diseases through the creation of a digital twin.

Cure heart

This project aims to provide a cure for inherited, killer heart muscle diseases. Led by Professor Hugh Watkins, BHF chair of cardiovascular medicine at the University of Oxford, these researchers will develop a treatment that targets and silences the faulty genes responsible for cardiomyopathies diseases of the heart muscle that can lead to sudden death at an early age. They intend to combine a deep understanding of underlying genetic mechanisms with new technologies, to stop the progression of the damage caused by genetic heart muscle diseases, or even reverse the damage.

Professor Sir Nilesh Samani, medical director at the British Heart Foundation, said: Heart and circulatory diseases remain the number one cause of death worldwide.

Were taking small steps forward every year but whats needed is a giant leap, which wont be achieved by a business-as-usual approach.

The Big Beat Challenge embodies our ambition to turbo-charge progress and could lead to its own man on the moon moment. I have absolutely no doubt the winning idea will define the decade in their area.

The teams will prepare their final applications by June 14, with interviews in early September and a decision expected by the end of the year.

Read more

Our guide to the Cambridge Science Festival 2020

Can HIV be cured? Evelyn Trust-funded research at University of Cambridge probes viral latency

Inside the Cambridge lab in pole position to create a new coronavirus vaccine

Sanger Institute scientist helps unveil blueprint for extraordinary Human Cell Atlas

Prof Greg Hannon on taking over at the Cancer Research UK Cambridge Institute and creating the worlds first virtual reality tumour

Read more from the original source:
Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes - Cambridge Independent

Aspiration-assisted bioprinting for precise positioning of biologics – Science Advances

INTRODUCTION

Aggregated cells have been formed into spheroids (13), honeycombs (4), and strands (5) from a variety of different cell types and their cocultures. They have many advantages including the cellular capability to secrete extracellular matrix (ECM) components with an effective communication between cells in a native-like microenvironment (1). When cells are grown in an isolated fashion (i.e., cells in monolayers or cell-laden hydrogels), they usually do not facilitate native-like tissue microenvironment because of limited cell-cell and cell-ECM interactions (6). Three-dimensional (3D) cell aggregates, particularly tissue spheroids, are excellent candidates to mimic in vivo tissue microenvironments, which can be reconstituted to form reproducible complex tissues [such as bone (7) and pancreas (8)] and or tissue models [cancer (9)]. Furthermore, cocultured aggregates can be used as building blocks for fabricating scalable tissue complexes (2). Spheroids loaded with endothelial cells can also facilitate a denser tissue microenvironment, inherent ECM secretion, and prevascularized network (10). As a result, large-scale vascularized tissue complexes can be biofabricated using prevascularized cell aggregates as fundamental building blocks (7, 11), which allow more accurate representations of native tissues. Moreover, these tissue complexes stand to develop physiologically correct models for drug screening, disease modeling (i.e., cancer), and high-throughput screening (12). Therefore, various advantages of tissue spheroids make them a great candidate as building blocks for 3D bioprinting.

Despite these advantages, only a few methods including extrusion-based bioprinting (2, 11, 13, 14), droplet-based bioprinting (15), Kenzan (16), and biogripper approaches (4, 17) have been demonstrated for 3D bioprinting of spheroids made of cells, such as but not limited to human articular or nasal chondrocytes, human umbilical vein endothelial cells (HUVECs), human umbilical vein smooth muscle cells, etc. Extrusion-based bioprinting technique dispenses similar-sized spheroids suspended in a hydrogel ink through a glass nozzle. During bioprinting, spheroids in the hydrogel ink may self-aggregate inside the nozzle, leading to clogging issues (2). Although extrusion-based bioprinting of cellular aggregates in the form of strands can generate scalable tissues (3, 5), their use in high-precision applications, such as organ-on-a-chip platforms or microphysiological systems, is quite challenging. In droplet-based bioprinting, a single spheroid is loaded into a droplet during bioprinting, which enables the positioning of spheroids in 2D (15). Kenzan method uses an array of needles on which spheroids are skewered by a robotic arm; however, this method requires same-size spheroids since bioprinted spheroids have to fit properly in the needle array and smaller spheroids would be prone to fragment during insertion on the needle (16). Recently, the biogripper technique was introduced to manipulate defined micromolded tissue blocks. However, this technique enables bioprinting of only molded tissue blocks in the range of 600 m to 3.4 mm, where submillimeter scale is quite large for typical tissue building blocks (4, 17). All the existing techniques used in the literature suffer from the positional accuracy and precision of spheroid bioprinting; may induce substantial damage to biological, structural, and mechanical properties of spheroids; and are limited to the use of same-size spheroids for successful bioprinting.

Here, we present a new hybrid bioprinting approach through harnessing the power of aspiration forces, which enables us to pick and precisely bioprint a wide of range of biologics, with dimensions in an order-of-magnitude range (80 to 800 m), into/onto a gel substrate with minimal cellular damage. To better understand the response of biologics to the bioprinting process, we unveil the underlying mechanism explaining the physical behavior of viscoelastic spheroids and their interactions with physical governing forces during aspiration, lifting, and bioprinting. Compared to the abovementioned methods, the presented approach facilitated the bioprinting of spheroids in higher positional precision and accuracy, ~11 and ~15% with respect to the spheroid size, respectively. In addition, it enabled bioprinting in 3D with flexibility of bioprinting of nonuniform, any-size spheroids into (i) a functional gel as a scaffold-based approach or (ii) a sacrificial gel as a scaffold-free approach (Fig. 1). The newly developed aspiration-assisted bioprinting (AAB) platform, modified from a MakerBot Replicator 1 (<$1000) (see fig. S1), operates a custom-made glass pipette, which is used to pick up biologics and 3D bioprint them into or onto a gel substrate. AAB was coupled with microvalves for droplet-based bioprinting of functional or sacrificial hydrogels. To bioprint spheroids into a functional hydrogel (i.e., fibrin), fibrinogen and thrombin layers were printed via microvalve bioprinting to obtain fibrin constructs. Spheroids were then bioprinted into desired positions before the constructs were fully cross-linked. To bioprint spheroids onto a sacrificial hydrogel (i.e., alginate), microvalve bioprinting and aerosol cross-linking processes were used. The first step included the generation of sodium alginate droplets on a glass substrate. Second, calcium chloride (CaCl2) was fumed for instant cross-linking (18). Spheroids were then picked and 3D bioprinted onto the partially cross-linked alginate. Next, the print area was overlaid with sodium alginate droplets. Then, aerosol form of CaCl2 was applied again. The process was then repeated as many times as needed for building other layers. Next, bioprinted spheroids were maintained in the support gel temporally until partial fusion was realized. Last, the support gel was gently removed through decross-linking using a lyase solution.

In step 1, spheroids are picked from the cell media by a glass pipette, where required back pressure is set to lift spheroids. Afterward, spheroids can be bioprinted into sacrificial hydrogels (scaffold-free bioprinting) or functional hydrogels (scaffold-based bioprinting). In this regard, in step 2, microvalve bioprinting is used to bioprint a gel substrate, which can then be partially cross-linked using various different cross-linking schemessuch as but not limited to enzymatic, photo, and ionic cross-linkingas highlighted in step 3. Next, in step 4, spheroids are bioprinted precisely into designed positions, and spheroid bioprinting is repeated as many times as needed. Steps 2 to 4 can be repeated as needed. In step 5, bioprinted tissues are isolated from the support hydrogel (for scaffold-free bioprinting) or further grown in the functional hydrogel (for scaffold-based bioprinting). UV, ultraviolet.

The presented approach paves the way for bioprinting several tissue types and a wide range of spheroids in 2D and 3D in gel substrates with multiple applications presented throughout this paper, including (i) the development of physiologically relevant culture environments to demonstrate the collective angiogenic sprouting behavior of spheroids in a scaffold medium and (ii) fabrication of osteogenic tissues to decode the role of midterm osteogenic induction of stem cellbased spheroids (before bioprinting) on the mineralization and assembly behavior in a scaffold-free environment. In addition to spheroids, other living cells and tissue building blocks, including electrocytes from electric eel and tissue strands, can be bioprinted for a wide variety of applications, such as but not limited to tissue engineering, regenerative medicine, drug testing and pharmaceutics, disease modeling, microphysiological systems, biophysics, and biocomputing.

In the AAB process, the first step is to pick a spheroid (fig. S2) and then lift it and drag it rapidly outside the culture media by aspiration forces as shown in Fig. 2A. The spheroid should be captured with a minimum aspiration force to transfer but not break or damage it. During aspiration under an applied stress (), a spheroid with viscoelastic properties exhibits both viscous and elastic properties (19). It exhibits elastic properties like a solid at times shorter than relaxation time and like a fluid for t > , which can be described by the Maxwell modelddt+=ddt(1)where is the strain and is the modulus of elasticity of spheroids. During this process, two major impediments were experienced. First, spheroids were prone to fragment because of low cellular cohesivity and elasticity even under very low pressure levels. Second, detachment of spheroids from the pipette tip at the three-phase contact (air-liquid-tissue) was observed during lifting. The former can be mitigated by engineering of spheroids to attain better elastic properties [such as culturing them longer (20) or incorporating cells expressing higher cell-cell and cell-matrix adhesion or ECM proteins (21)], and the latter can be addressed by determining the minimum aspiration pressure (critical lifting pressure). A spheroid is lifted by pipette aspiration after overcoming gravity, buoyance force, hydraulic drag, and thermodynamic barrier at the interface. The main difficulty in lifting a spheroid is the binding energy caused by the surface tension at the interface between the culture media and air. The spheroid contributes to the lifting barrier in the form of a contact angle at the three-phase (tissue, air, and media) contact line. The energy barrier to lift a spheroid into air can be expressed asE=As1,2cos2d2(2)where As is the surface area of a spheroid, 1,2 is the surface tension between the media and air, and d is the contact angle at the three-phase contact line. During lifting, the three-phase contact angle (dynamic contact angle) is greater than the static contact angle because of dynamics effect (22). The dynamic contact angles of spheroids made of several types of cells were enumerated in table S1. By comparison, the thermodynamics barrier is about 500 times of gravity, 100 times of Stokes drag, and 5 times of Young-Dupre critical pressure. During lifting, the energy barrier can be estimated by adding a geometrical correction factor (m) as a result of slight changes in the spheroid geometry due to the aspiration of a tongue (see Fig. 2B). The initial contact length of the tongue (ht=0) of a spheroid ranges between Rp and 2Rp. Thus, m can be defined as followsm=14Rp24RS24Rp2=1Rp2RS2Rp21(RpRs)2(3)

In Eq. 3, Rp is the pipette tip radius and Rs is the spheroid radius. m can be approximated to 1 when the spheroid radius is much larger than the radius of the pipette tip. However, when lifting a small spheroid or when the radius of the pipette is comparable to that of the spheroid, m becomes much smaller. Consequently, the critical lifting pressure of a spheroid (PC) from the media can be expressed as follows (22)PC=mFmax/Ah=2mRS1,2cos2d2/(Rp2)(4)

The critical lifting pressure is proportional to the surface tension coefficient of the media-air interface, the radius of the spheroid, the dynamic contact angle at the three-phase contact line, and the tapered angle of the pipette (influences Rp, but this parameter was fixed).

(A) Time-lapse images during spheroid lifting process (at the interface of cell media and air). (B) A schematic showing physical parameters involved in lifting of a spheroid from the cell media. (C) SEM images, (D) surface tension (n = 5), and (E) the normalized collagen content of HUVEC, 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids (compared to HUVEC spheroids) at day 2 (n = 4; *P < 0.05, **P < 0.01, and ***P < 0.001). (F) Critical lifting pressure to lift spheroids (in the range of 200 to 600 m in diameter) (n = 5). The experimental data spread under the theoretical curve, which was determined using the experimental data for 4T1 spheroids with parameters (d = 64 and s1,2 = 57.4 mN/m). Spheroids made of other cell types had lower theoretical critical lifting pressure values (data are not shown in the paper). For instance, the theoretical critical lifting pressure for HUVEC spheroids was 20% smaller than that of 4T1 spheroids. (G) Viscoelastic behavior of spheroids under aspiration (n = 3). Here, h denotes the advancement of spheroids inside a glass pipette. The aspiration experiment used a similar pipette as that in bioprinting. The aspiration pressure was determined according to the size of spheroids satisfying the condition that spheroids could be lifted from the cell media.

To demonstrate picking and lifting of spheroids, we fabricated a wide range of spheroid types with different viscoelastic and surface tension properties using HUVECs, mouse fibroblast cell line (3T3), mouse mammary carcinoma line (4T1), human dermal fibroblasts (HDFs), coculture of human mesenchymal stem cells (MSCs) and HUVECs, and MSCs. Various kinds of spheroids in a diameter range of 200 to 600 m were obtained using cell-repellent 96-well plates. Spheroids were fabricated at a cell density from 2500 to 10,000 per spheroid and cultured for 1 to 3 days (fig. S3A). During the first 24 hours, we closely monitored spheroid formation and observed that 3T3 and HDF spheroids became compact and withstood aspiration forces at the end of 20 hours, while others became compact at 24 hours, implying that these spheroids could be lifted anytime thereafter (fig. S4). To investigate the ultrastructure of spheroids, spheroids were analyzed by scanning electron microscopy (SEM), and SEM images demonstrated clear differences in surface morphology and compactness of different spheroids cultured for 2 days (Fig. 2C). The surface topology of MSC spheroids displayed a substantial amount of secreted ECM with smoother and more compact structure due to tight cell-cell and cell-ECM interactions. On the other hand, the surface topology of HUVEC spheroids displayed lesser ECM compound, which resulted in a pitted surface and tiny gaps between cells. To lift spheroids, spheroids were required to be compact and captured in the cell media and to withstand aspiration forces. Spheroids also have surface tension, with each cell being analogous to a liquid molecule (23, 24). Thus, surface tension of spheroids were investigated by a micropipette aspiration technique (19, 25) according to the Young-Laplace equation, which gave the relationship between the internal pressure of spheroids and cell media across a curved interface. According to the Young-Laplace equation, the surface tension coefficient can be estimated as =P2(1/Rp1/Rs), where P is the equilibrium aspiration pressure when the advancement of the spheroid inside the pipette was the same as the radius of the pipette tip. As shown in Fig. 2D, the surface tension of HUVEC, 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids at 2 days of culture were measured to be ~14, 30, 37, 41, 51, and 66 mN/m, respectively. Surface tension of MSC-only spheroids was approximately five times higher than that of HUVEC spheroids. It is worth mentioning that Norotte et al. (26) used a different method to measure the surface tension of spheroids and obtained a similar result for HUVEC spheroids. While the surface tension of 4T1, HDF, and MSC/HUVEC spheroids increased over time, the surface tension of spheroids made from other cell types maintained similar properties during the 3-day culture (fig. S3B). This time frame, on the other hand, can vary for spheroids prepared using other techniques, such as but not limited to handing drop, microfluidic, rotator flask, and liquid overlay methods (27). Our results indicate that there is a positive correlation between the surface tension of spheroids and their compactness, confirming previous findings by Foty and Steinberg (28). In addition, the total collagen amount of spheroids was investigated using a hydroxyproline colorimetric assay kit since collagen is one of the major ECM components of spheroids (3). The measured collagen amount for 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids at day 2 was ~1.4-, 1.4-, 1.5-, 2.8-, and 3.4-fold higher compared to that for HUVEC spheroids, respectively (Fig. 2E). The normalized collagen content in different spheroids showed a similar trend as compared to the compactness of spheroids; however, we did not observe any notable differences among the normalized collagen content for 3T3, 4T1, and HDF spheroids. A recent study reported a positive correlation between compactness of cell aggregates and their collagen expression (29).

Figure 2F denotes a linear relationship between the critical lifting pressure and diameter of spheroids (in the range of 200 to 600 m). When the diameter of spheroids increased, the critical lifting pressure also increased. The theoretical critical lifting pressure for each spheroid types at different diameters were determined using Eq. 4, where the maximum theoretical value belonged to 4T1 spheroids, which could be used as a baseline for other spheroid types to be tested during aspiration. In addition, the minimum critical lifting pressure among all spheroids types (from 200 to 600 m) was determined to be ~19 mmHg. The difference between the theoretical and experimental value of the critical lifting pressure was due to (i) the irregular shape of spheroids (elliptic or pancake-like) influencing the maximum energy barrier (30, 31) and (ii) the measurement inaccuracy of the pressure sensor (which was around 10%; see fig. S5, A and B). Another vital factor for successful bioprinting was to determine viscoelastic properties of spheroids, which were reflected by the relationship between stress and strain as a function of time. During the AAB process, spheroids were kept within a solid elastic regime. The operation time of AAB was defined by the elapsed time between spheroid picking and bioprinting, which was commonly less than 30 s. Therefore, spheroids were successfully bioprinted, while their relaxation time () was longer than the bioprinting operation time. For this reason, we plotted the aspiration curves of various spheroids (Fig. 2G). At the early stage of aspiration, spheroids deformed very quickly within the elastic regime. Then, after a relaxation time, accumulated stress was gradually released, and spheroids experienced a relaxation process and return to their original shapes. As shown in Fig. 2G, the relaxation time for HUVEC, 4T1, and MSC/HUVEC spheroids were around 3 to 5 min. The relaxation time for HDF spheroids could reach up to 18 min. Overall, these relaxation times were sufficient to assure successful bioprinting without permanent deformation to spheroids.

After lifting spheroids from the cell media and transferring them to the bioprinting stage, the back pressure was released, and the spheroids were fully recovered or, in other words, they returned to their original shapes as bioprinting time was less than the relaxation time. To bioprint a spheroid, the spheroid was partially submerged into a precross-linked or partially cross-linked gel substrate, as going deeper could result in their breakage due to penetration of the pipette tip into the spheroid. When the nozzle moved up, the spheroid was stuck to the gel because of adherence between the spheroid and the gel (Fig. 3A1), released from the pipette, and deposited into the gel. In AAB, successful bioprinting was determined by a constant adherence at the pipette tip (upward, Fup) and a variable bioprinting force at the interface of gel (downward, Fdown). To determine Fup, two angles were defined: 1=arccosRpRs, and 2 is the pipette taper angle. Fup can be expressed as Fup = 2Rps cos (1 + 2), where s is the surface tension of the spheroid. At the bottom of the spheroid, the maximum force pulling the spheroid downward due to the surface tension of the gel substrate, i.e., the maximum bioprinting force provided by the gel, can be expressed as Fdown=2Rsgcos2(12). Here, g is the surface tension of the gel, and 1 is the effective angle of wetting. For successful bioprinting, the maximum force pulling the spheroid downward needs to overcome the surface tension adherence at the tip of the pipette. Thus, successful printing, as shown in Fig. 3A2, needs to satisfy the condition Fdown > Fup. However, if a spheroid is not fully recovered (when the spheroid is submerged rapidly into the gel), there can be an extra stress (Fext) at the pipette tip. The extra stress may increase the difficulty of bioprinting since Fdown needs to overcome Fext + Fup.

(A1) A schematic showing critical parameters during bioprinting. (A2) An image from the traveling camera showing spheroid placement onto a gel substrate. Fluorescent images showing (A3) PSU and (A4) matrix patterns. GFP+ MSC spheroids were patterned onto (A5) COL I and (A6) gelatin-methacryloyl (GelMA). (A7 and A8) Images showing that eight fixed spheroids were bioprinted on top of each other in air without any gel support during bioprinting. DAPI, 4,6-diamidino-2-phenylindole. (B1) Time-lapse images of self-assembly process after bioprinting of 1-day cultured 3T3 spheroids at 0, 24, 48, and 72 hours (B2) and the normalized contact length and intersphere angle of fusing spheroids up to 24 hours. (B3) Cell viability of 3T3 spheroids that were not treated with bioprinting (control), after bioprinting inside the cell media (case 1), and after bioprinting into a gel substrate (case 2) (n = 3; *P < 0.05). CMTMR, 5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethylrhodamine; CMFDA, 5-chloromethylfluorescein diacetate. (C1) Hematoxylin and eosin staining from the sagittal plane of a tail segment of electric fish showing stacked electrocytes in series. (C2) The SEM image of a single electrocyte. (C3) Calcein staining of bioprinted electrocytes. (D) A bioprinted cartilage tissue strand between pins. Photo credit: Bugra Ayan, Penn State University.

To verify the presented theoretical approach, we measured 1, 2, and 1 angles and obtained the surface tension of precross-linked gel [1% (w/v) alginate] from the literature (32). The results indicated that Fdown was ~32, 14, 12, 11, 9, and 7 times greater than Fup for HUVEC, 3T3, 4T1, HDF, MSC/HUVEC, and MSC spheroids, respectively, as enumerated in table S2. Surface tension of gel solutions can vary from gel to gel. In some gels [such as alginate (32)], surface tension is dependent on concentration; however, there are hydrogels where surface tension is not dependent on concentration, such as polyacrylamide (33). Therefore, we cannot make a general statement on the correlation between concentration and surface tension. In addition, concentration of the gel should also be compatible with microvalve bioprinting, as higher concentrations of precursor solutions are, in general, bioprintable as such concentrations can support droplet formation (34). For bioprinting into a gel substrate, the gel precursor solution should be flowable as well so that the solution can overlay the bioprinted spheroid quickly; therefore, we performed bioprinting on partially cross-linked or uncross-linked gel precursor.

Before performing the patterning and 3D bioprinting of spheroids, we first inspected the quality of positioning during bioprinting. In this regard, agarose beads (with near-perfect sphericity) and the motion stage of the 3D bioprinter were used as control groups. The positional precision and accuracy for the motion stage (empty pipettes), spherical agarose beads (ranging from 250 to 300 m in diameter), and 2-day cultured MSC/HUVEC spheroids (~300 m in diameter) were determined to be ~2 and 2.1 m, 14.4 and 10.4 m, and 34.7 and 45.9 m, respectively (fig. S5, C to E). The results indicate that the bioprinter motion stage had a small effect on the positional error during bioprinting and that bioprinting of spheroids was about two- and fourfold less precise and accurate compared to printing of agarose beads, respectively. This could be due to the viscoelastic nature, lesser sphericity, and slightly higher average diameter of tissue spheroids compared to more rigid agarose beads. We demonstrated the ability to bioprint spheroids precisely (~11% with respect to the average spheroid size) onto alginate through patterning of various shapes (fig. S6, A1 to A3), initials of Penn State University (PSU) (Fig. 3A3), and a matrix of spheroids of various shapes and dimensions (including irregular shapes) in the diameter range of 80 to 200 m (made of HUVEC, 3T3, and 4T1 cells) (Fig. 3A4). Moreover, we also demonstrated the bioprinting of green fluorescent protein (GFP)labeled MSC spheroids in the shape of triangle and ring into other gels, including type I collagen (COL I) and gelatin methacryloyl (GelMA), as shown in Fig. 3 (A5 and A6, respectively). To highlight the unprecedented precision of AAB, we bioprinted eight different-sized MSC spheroids on top of each other without any gel support (Fig. 3, A7 and A8) and also fabricated a hollow bridge shape with MSC spheroids using the same approach (fig. S6, B1 and B2). Moreover, we demonstrated another example of a hollow bridge configuration, where the middle spheroid in the second layer was supported by the underlying gel without any spheroid support underneath (fig. S7). This was accomplished by bioprinting the gel and spheroids alternatingly at each layer, which necessitated the precise control of gel thickness; however, the gel thickness was dependent on several factors, such as the droplet resolution, cross-linking time, and spreading behavior of droplets, which were not trivial to control at the same time using microvalve bioprinting. To overcome this fundamental limit, self-healing Bingham plastic support gels (35) could be used to freely move the spheroids inside gels, which may bring more flexibility in self-assembly of highly complex geometries including hollowed-out structures.

In addition, self-assembly of spheroids was investigated at predetermined time points. As shown in Fig. 3B1, 3T3 spheroids were bioprinted into fibrin with close proximity and then cultured for 72 hours. The two individual 3T3 spheroids bioprinted next to each other gradually fused to form a larger spheroid to minimize their surface energy, as described in a previous study (21). The normalized contact length and intersphere angle increased by 50% over the first 24 hours of culture (Fig. 3B2). To evaluate the role of bioprinting on the viability of spheroids, two cases were evaluated. In case 1, the viability of spheroids was determined immediately after lifting spheroids and depositing them into another cell medium reservoir. In case 2, the viability of spheroids was evaluated after bioprinting them into the gel substrate. Spheroids, which were not subjected to the bioprinting process, were used as a positive control group. The viability of spheroids in the positive control group and case 1 were determined to be ~94 and ~88%, respectively (Fig. 3B3). In case 2, cell viability was measured to be ~82%. The decrease in cell viability could be due to the aspiration force or dehydration during the rapid transfer or cell damage when spheroids were submerged into the hydrogel substrate; however, viability levels over 80% for bioprinting of spheroids could still be considered moderate, as viability of fabricated cells aggregates even without bioprinting could be in that range (36).

In addition to bioprinting of spheroids, the AAB system also enabled the bioprinting of other biologics. For example, we demonstrated the bioprinting of electrocytes isolated from electrogenic organs of electric fish. Because of the asymmetric functionality of their anatomy and their spatial arrangements in series configuration in an electric organ (similar to batteries connected in series; Fig. 3C1), electrocytes produce a considerable amount of electricity (37). In this study, five electrocytes (~400 m in diameter; Fig. 3C2) from weakly electric fish (Brachyhypopomus gauderio) were obtained according to the animal protocol (Institutional Animal Care and Use Committee #47870) and patterned next to each other onto agarose using AAB with a back pressure of ~20 to 25 mmHg (Fig. 3C3). To the best of our knowledge, this is the first bioprinting of electrocytes, which can be used in biofabrication of biological batteries for various applicationssuch as pacemakers, cochlear implants, and brain chipsin the future (38). In addition, these cells could be arranged in the form of biological circuits for biocomputing or as bioelectric interfaces for use in treating limb loss, musculoskeletal disorders, and body augmentation as well as cyborg organs interfacing electrical devices and biology (39). The presented approach showed the possibilities of bioprinting not only spheroids or single cells but also irregularly shaped aggregates. For example, Fig. 3D shows vertical bioprinting of tissue strands [described in our previous work (5)] into the space between pins, which can be used for fabrication of scalable tissues of muscle, fat, cartilage, nerves, blood vessels, etc.

To demonstrate other unique capabilities of the presented approach, heterogeneous tissue complexes were 3D bioprinted using spheroids of different sizes and types including tdTomato+ HUVEC spheroids (~155 m) and GFP+ MSC spheroids (~390 m) (Fig. 4, A and B). Spheroids were arranged into a pyramid structure to clearly visualize the heterogeneous architecture using confocal imaging, where alginate was used as a sacrificial gel and the first, second, and third layers constituted of HUVEC, MSC, and HUVEC spheroids, respectively. This example clearly demonstrates the unique deposition ability of the AAB technique, as the last HUVEC spheroid was accurately placed into the small and confined space between three adjacent MSC spheroids (~2.5-fold of HUVEC spheroid size) on the third layer. Alginate preserved the structural integrity of the bioprinted pattern during the initial stage of culture. Moreover, it enabled the bioprinted entities to stick in their precise locations, which were defined before the bioprinting process. To print the sacrificial alginate, we used a unipolar wave pulse with a dwell voltage (amplitude) of 5 V and a dwell time (valve opening duration) of 1000 s for actuating the microvalve dispenser, where a positive back pressure of ~103 kPa was used for driving the flow of sodium alginate inside the tubing. The reader is referred to fig. S8A for the optimization of dwell time and droplet volume. Afterward, sodium alginate layer was partially cross-linked with aerosol form of CaCl2 for 30 s, and spheroids were bioprinted as explained in Fig. 1. Patterned spheroids were partially fused and maintained their initial position after 48 hours of incubation. After 2 days of culture, alginate was gently dissolved [using an alginate lyase as explained in our earlier work (5)], and the bioprinted constructs maintained their integrity even after the sacrificial alginate was removed. As evident from the confocal images (Fig. 4, C1 to C6), spheroids were well connected in 3D. A similar arrangement was also presented with MSC spheroids of three different dimensions, where spheroids got larger as more layers were laid down (fig. S9, A to C). We also demonstrated a more complex pattern such as a 3D diamond pattern with MSC/HUVEC spheroids (Fig. 4, D to G). To the best of our knowledge, this is the first bioprinting of tissue spheroids with such a positional accuracy, ~15% with respect to the spheroid size, yielding highly intricate geometries and heterogeneous structures in 3D.

(A) A schematic illustration of 3D bioprinting of a heterogeneous pyramid construct using different sizes and types of spheroids. (B) A photograph of the bioprinted three-layer heterogeneous pyramid. (C1 to C6) 3D reconstruction of confocal images of bioprinted pyramid of tdTomato+ HUVEC spheroids (first and third layers) and GFP+ MSC spheroids (second layer). (D) A schematic illustration of a diamond construct made of MSC/HUVEC spheroids. (E) A photograph showing 3D bioprinted diamond from the side camera. (F) Fluorescent images of the bioprinted diamond, which were stained with DAPI, CD31, and F-actin. (G1 to G4) Confocal images of the diamond construct (bottom view) (note that 1-day cultured HUVEC and 2-day cultured MSCs were used in these experiments). Photo credit: Bugra Ayan, Penn State University.

In this study, we have demonstrated the utilization of AAB in both scaffold-based and scaffold-free configurations and presented two unique applications demonstrating its potential in the development of physiologically relevant culture environments for studying angiogenic sprouting and fabrication of osteogenic tissues for tissue engineering purposes. To demonstrate the application of AAB in scaffold-based fabrication of physiologically relevant culture environments, we bioprinted HUVEC spheroids into fibrin hydrogel with a predetermined distance apart and studied their collective angiogenic sprouting behavior. This importantly signifies that angiogenic sprouting behavior can be tailored by varying the proximity of spheroids, hence directly affecting cell-cell signaling. To study the effect of distance on angiogenic sprouting, we deposited droplets of fibrinogen (6 mg/ml) [loaded with HDFs (0.5 million/ml)] and thrombin (2.4 U/ml) layer by layer (in 1:1 volume) to fabricate fibrin constructs, as such concentration ranges support angiogenesis of HUVECs (40). A positive back pressure of ~103 kPa was used for driving the flow of fibrinogen and thrombin solutions inside the tubing and dispenser. To dispense a ratio of 1:1 of fibrinogen and thrombin, we used dwell times of 500 and 700 s for obtaining the same droplet volumes at the microvalve dispensers, respectively. The reader is referred to fig. S8 (B and C) for the optimization of droplet generation for fibrinogen and thrombin solutions. HUVEC spheroids were then bioprinted into fibrin before complete gelation. The distances between the spheroids were maintained at 400 10, 800 13, and 3000 16 m (isolated spheroids used as a control group) (Fig. 5A1). Bioprinted constructs were cultured for a period of 7 days. Angiogenic sprouting from HUVEC spheroids at days 2, 5, and 7 was quantified using AngioTool software (41). Spheroids with close proximity to each other were seen to have higher total vessel length as compared to isolated spheroids right from the initial stages of culture. The combined length of sprouts was 13 and 11 mm for 400 and 800 m, respectively, as compared to the control group, which were around 6 mm (Fig. 5A2). A similar trend was also observed for the total vessel area. There was approximately 3- and 2.5-fold increase in the vessel area for 400- and 800-m distances on day 7 as compared to the control group, respectively. Although the total number of branching points or junctions was not significantly different among different groups at day 2, the sprouts branched more when spheroids were bioprinted close to each other, as compared to the control group (fig. S10). On day 7, the number of junctions for 400- and 800-m distances was 2.1- and 1.7-fold greater than those for the control group, respectively. The mean lacunarity refers to the amount of free space around the sprouted capillaries, and an increase in angiogenic sprouting results in a decrease in lacunarity (42). This yields a measurement of the sprouting activity, and the mean lacunarity was the highest for the control group compared to other two groups.

(A1) Epifluorescent images of bioprinted tdTomato+ HUVEC spheroids with varying distances (400 to 3000 m) apart on day 7. (A2) Graphical representation of various sprouting propertiesnamely, total vessels length, total number of junctions formed, vessel area, and mean lacunarityobtained at day 7 for bioprinted HUVEC spheroids (n = 3; ***P < 0.001). (B1) Epifluorescent images of bioprinted GFP+ and tdTomato+ HUVEC spheroids with varying distances (400 to 3000 m) apart on day 7 along with higher-magnification confocal images of the interface region in XY and YZ planes showing capillaries formed by both GFP+ and tdTomato+ HUVECs (indicated by white arrows). (B2) Directionality analysis demonstrating the direction and percentage of normalized number of sprouts on day 7 (n = 3; *P < 0.05, **P < 0.01, and ***P < 0.001) [note that green and red bars demonstrate the angles of interest (AOIs), which are [60, 60] for GFP+ HUVECs and [120, 240] for tdTomato+ HUVECs]. (B3) Confocal images at the interface of two spheroids showing capillaries formed by both GFP+ and tdTomato+ HUVECs. (C1) A schematic illustration of the directionality of sprouts from a HUVEC spheroid toward a spheroid of GFP+ HDF and MSC cocultures. (C2) The directionality analysis for different mixing ratios of HDF:MSC, including HDF (control), 2:1, 1:1, and MSC (control), on day 7 (n = 3; ***P < 0.001 shows significance between AOI and Other for each group, and #P < 0.05, ##P < 0.01, and ###P < 0.001 show significance among AOIs of different groups) [note that N/A represents the none applicability of the directionality analysis, as no sprouts were observed in the MSC-only group; no directionality analysis was performed for the 3000-m distance, as sprouting was not observed and HUVECs exhibited spreading only; 1-day cultured HUVECs were used in all experiments; and the critical lifting pressure for coculture HDF/MSC spheroids (2:1 and 1:1 ratio) was determined to be 28.7 and 29.1 mmHg, respectively, through interpolation of the critical lifting pressure values for HDF and MSC spheroids presented in Fig. 2F].

In our study, HUVEC spheroids bioprinted with 400- and 800-m distances apart were considered to be in close proximity. On the other hand, HUVEC spheroids bioprinted with 3000-m distance apart were far enough to be considered isolated spheroids (control group). Proximity between cells triggers a cascade of events that, in turn, influences cellular behavior, and to study these events, it is important to control localization under in vitro conditions (43). The presented approach offers the capability of controlling the distance between spheroids and thus aims to better understand this signaling between spheroids. Sprouting properties such as vessel length, junction formation, and vessel area were all enhanced when spheroids were close to each other as compared to when they were placed far apart. The presence of HDFs in the matrix surrounding HUVEC spheroids also reinforced the formation of stable sprouts. It is known that fibroblasts act as supporting cells and surround the capillary-like structures, which gradually develop by self-organization of endothelial cells and simultaneous degradation of fibrin matrix (44). Moreover, fibroblasts secrete various soluble growth factors such as vascular endothelial growth factor (VEGF), angiopoietin-1, platelet-derived growth factor (PDGF) (45, 46), which enhance and modulate the growth of angiogenic sprouts (47). Bioprinted HUVEC spheroids close to each other probably up-regulated the combined secretion of these growth factors in the vicinity of the spheroids, which led to enhanced sprouting properties. The sprouts from closely placed spheroids extended toward each other and gradually fused to form a capillary network.

To better understand whether the positioning of spheroids affected their collective angiogenic sprouting behavior, GFP+ and tdTomato+ HUVEC spheroids were bioprinted into fibrin gel (with same properties as discussed before) at 400-, 800-, and 3000-m distances apart, and cultured over a period of 7 days (Fig. 5B1). A directionality analysis was then performed to investigate the role of the presence of a nearby spheroid on the directionality of angiogenic sprouting. Thus, the angle made by each sprout with the horizontal line (0/180) was measured for all spheroids. The angle spans [60, 60] for GFP+ HUVEC and [120, 240] for tdTomato+ HUVEC spheroids, where sprouts primarily grew toward the other spheroid, were considered the angles of interest (AOIs), as highlighted in Fig. 5B2. On day 7, the percentage of normalized number of sprouts (where the total number of sprouts were normalized with respect to the total angle span) in AOI was significantly higher than that of the other angle span (indicated with Other) for 400- and 800-m distances, indicating a dominating directionality of angiogenic sprouting toward the other spheroid. The percentage of normalized number of sprouts for AOI was ~63 and 65 for GFP+ and ~59 and 61 for tdTomato+ HUVEC spheroids, for 400- and 800-m distances, respectively. Although the directionality of sprouts for all cases may not be very apparent on day 2 (initial stages of culture; fig. S11, A1 and A2), on day 5 (later stages of culture; figs. S11, B1 and B2, and S12), mature sprouts were more concentrated within AOI. In addition, for sprouts formed in directions falling outside the AOI (depicted in gray), we observed more random growth of sprouts over time. The sprouts for spheroids that were 3000 m apart were random and did not indicate any directionality from days 2 to 7 (Fig. 5B2, bottom, and fig. S12C). For 400-m distance, it was also observed that the GFP+ HUVECs suppressed the sprouting ability of tdTomato+ HUVECs day 2 onward, where higher numbers of GFP+ HUVEC sprouts were observed at the interface [see fluorescent images in fig. S11 (A1 to B1)]. Domination of GFP+ HUVEC sprouts could be due to the fact that GFP+ HUVECs in this experiment were from an earlier passage (passages 2 to 5) with respect to tdTomato+ HUVECs (passages 5 to 7) (48). In addition, we investigated whether sprouts from both spheroids interacted and thus performed confocal imaging at the interface close to the tdTomato+ HUVEC spheroid (Fig. 5B3). We noticed that some capillaries were formed by both GFP+ and tdTomato+ HUVECs, as shown by arrows, which could be due to vascular anastomosis or the migration of GFP+ HUVECs to the other side of the interface and their contribution to the capillary formation by tdTomato+ HUVECs spheroids. Overall, the results showed that HUVEC spheroids bioprinted close to each other influence each others sprouting behavior, which led to a well-organized network formation between the sprouting bodies.

In the abovementioned experiments, we investigated the role of multiple HUVEC spheroids on their collective sprouting behavior, where HDFs were bioprinted as a single-cell suspension in fibrin, had direct contact with HUVEC spheroids, acted as supporting cells, and aided in forming stable sprouts. To explore whether HDFs could still influence the sprouting behavior of HUVECs even when they were not in direct contact with HUVECs, we reconfigured the design of the experiments presented above. In this regard, a HUVEC spheroid was bioprinted along with a coculture spheroid of GFP+ HDFs and MSCs (with controlled distance apart), which enabled us to change the concentration of HDFs and study the differential effect of coculture composition on HUVEC sprouting. GFP+ HDF/MSC spheroids, in 2:1 and 1:1 ratios, were bioprinted next to tdTomato+ HUVEC spheroids in fibrin with the same properties as discussed before (Fig. 5C1). HDF and MSC (homocellular) spheroids were used as control groups. The distance between these spheroids were varied from 400 to 3000 m, as performed before. For the cases of 400 and 800 m, HUVECs were attracted toward spheroids of HDF, 2:1, and 1:1 groups and were seen arranging into sprouts over a period of 7 days (figs. S13 and S14). The directionality analysis on day 7 revealed that the percentage of normalized number of sprouts within AOI for HDF, 2:1, and 1:1 groups for 400-m distance were ~82, 80, and 67, respectively (Fig. 5C2). For 800-m distance, a similar directionality was observed, where the percentage of normalized number of sprouts within AOI for HDF, 2:1, and 1:1 groups were determined to be ~84, 81, and 76, respectively. On the other hand, spheroids in the MSC group (Fig. 5C2) or spheroids located apart with a 3000-m distance (fig. S15) did not induce sprouting day 2 onward; rather, HUVECs exhibited spreading behavior. On day 2, for the case of 800 m, although the tip cells from HUVEC spheroids were not observed to have any physical contact with HDFs at the interface of both spheroids, sprout-like structures were already formed (fig. S16A). These structures were directed toward HDFs, as the relevant directionality analysis revealed a significant difference between AOI and Other for HDF, 2:1, and 1:1 groups (fig. S16B). This could be due to the fact that HDFs communicated with HUVECs via paracrine signaling by the possible diffusion of secreted growth factors, such as VEGF, angiopoietin-1, and PDGF, as discussed before (45, 46). By day 5 when HDFs substantially migrated out of the coculture spheroids, HDFs interacted with HUVECs outside AOI, particularly within angle spans [60, 120] and [240, 300], and induced sprout formation in those directions (fig. S17). Overall, more stable sprouts were observed in HDF-involved spheroids, and the results revealed that better directionality of angiogenic sprouting could be attained when the density of HDFs increased in the coculture spheroid. The presence of MSCs, on the other hand, had a negative impact on angiogenic sprouting of HUVECs, which could be due to the inhibitory effect of MSCs on the angiogenic potential of HUVECs via cell-cell contact through modulation of the VE-cadherin/-catenin signaling pathway as described before (49, 50).

To demonstrate another major application of AAB, osteogenic tissues were bioprinted using MSC/HUVEC spheroids as building blocks in a scaffold-free configuration. After fabrication, two different osteogenic differentiation culture strategies were used, both with equal total exposure time of osteogenic induction. This was performed to decode the role of midterm osteogenic induction of stem cellbased spheroids (before bioprinting) on the mineralization and assembly behavior of generated tissues (fig. S18). In strategy no. 1, 2-day cultured spheroids were bioprinted into a triangle pattern (Fig. 6A). After bioprinting, triangle-shaped tissue complexes maintained their integrity and transformed into a more compact and dense structure after 3 days in proliferation culture conditions [growth media (GM)]. Spheroids in this triangle-shaped pattern self-assembled over time, where cells exhibited a viability of 83% after 5 days of incubation, and the assembled structure was further cultured for a period of 12 days in osteogenic media (OM) (Fig. 6, B and C). In general, MSCs cultured in OM express high levels of osteogenic markers (51). To confirm the osteogenic differentiation of bioprinted tissues, the early osteogenic differentiation marker, Runt-related transcription factor 2 (RUNX2), was used for immunohistochemical staining. At the same time, the presence of HUVECs was confirmed by CD31 staining. As shown in Fig. 6D, bioprinted tissues expressed osteogenic- and endotheliogenic-specific markers, as indicated by positive staining of RUNX2 and CD31. Calcium deposition of osteogenically differentiated tissues was also confirmed by Alizarin red staining. As shown in Fig. 6E, substantial calcium deposition was observed after 12 days of osteogenic induction, particularly at the core of the assembled tissue. As substantial contraction was observed after the fusion of MSC/HUVEC spheroids and the originally bioprinted triangular shape was not maintained (Fig. 6C) as well as the mineralization was not uniform throughout the tissue boundary (Fig. 6E), we also followed an alternative strategy (strategy no. 2) to preserve the bioprinted shape of osteogenic tissues (fig. S18). In this regard, MSC/HUVEC spheroids were first maintained in GM for 5 days, followed by inducting them with OM for 10 days. Next, spheroids were bioprinted and then kept for another 2 days in OM. In both strategies, the total exposure time to GM and OM was identical. At the end of culture (Fig. 6F), bioprinted tissues using strategy no. 2 exhibited strong expression of RUNX2 with more uniform distribution of mineralization demonstrated by Alizarin red staining, although RUNX2 staining was stronger in cores of spheroids (Fig. 6, G to J). Intensity analysis of RUNX2 revealed that RUNX2 staining was the strongest in the core of tissues or at the interface between spheroids and the weakest on the surface of the assembled tissues (Fig. 6, K and L, and fig. S19A), while CD31 staining was uniformly distributed throughout the histological sections of bioprinted tissues under both strategies (fig. S19B). A previous study demonstrated that HUVEC-mediated paracrine factors, including VEGF and the inflammatory mediator prostaglandin E2 (PGE2), promoted the osteogenesis of periodontal ligament stem cells under hypoxic conditions regulated by mitogen-activated protein kinase (MAPK) kinase/extracellular signalregulated kinase and p38 MAPK pathways (52). As the core of tissues and interface between spheroids were more hypoxic compared to the surface of assembled tissues, the osteogenic differentiation of MSCs could be further advanced in those regions by PGE2 and VEGF paracrine factors secreted by HUVECs. In addition, limited shape change was observed. This could be due to the fact that MSCs in MSC/HUVEC spheroids, cultured in OM for 10 days before bioprinting, were in the osteogenic differentiation pathway and their proliferation capability was diminished as reported in a previous study (53), and hence, limited contraction was observed in spheroids. Another advantage of strategy no. 2 is that the culture duration after bioprinting was reduced, where 2-day cultured tissues after bioprinting were still structurally stable. We also analyzed the expression levels of bone sialoprotein (BSP), type I collagen (COL1), alkaline phosphatase (ALP), RUNX2, and CDH2 (N-cadherin) genes for both strategies, and bioprinted tissues cultured in GM (labeled as 3D bioprinted tissue cultured with GM) and MSCs differentiated in 2D for 12 days (labeled as 2D MSCs cultured with OM) were used as control groups. As shown in Fig. 6M, expression levels of BSP, COL1, ALP, and RUNX2 genes for both strategies were similar to each other and significantly higher than those of control groups. In addition, the expression level of CDH2 gene (encoding N-cadherin protein) for all 3D bioprinted tissue groups were similar to each other and higher than that of the 2D control group. Overall, by changing the osteogenic induction window under the same total osteogenic induction duration, the shape of bioprinted tissues and uniformity of mineralization could be controlled, although no differences were detected in the expression levels of osteogenic genes.

Strategy no. 1: (A) Triangle-shaped tissue complexes were bioprinted using MSC/HUVEC spheroids and cultured for 3 days in GM and 12 days in OM. (B) Time-lapse images showing fusion of GFP+ spheroids up to day 15 (D15) after bioprinting. (C) An optical image showing the assembled tissue at day 15 after bioprinting. (D) Immunofluorescence staining (DAPI, CD31, F-actin, RUNX2, and DAPI + RUNX2) and (E) Alizarin red staining of the sectioned tissue. Strategy no. 2: (F) The final shape of the bioprinted tissue of osteogenic spheroids (cultured for 10 days in OM before bioprinting and 2 days in OM after bioprinting). Immunofluorescent images of (G) the bioprinted tissue and (H) confocal images of its histological sections stained for DAPI, CD31, and F-actin and (I) RUNX2 and DAPI + RUNX2. (J) Alizarin red staining of the tissue section. (K) Quantification of normalized RUNX2 intensity at different regions including the surface of assembled tissue, spheroid-spheroid interface, and core of spheroids (n = 50; **P < 0.01 and ***P < 0.001). (L) A representative heat map figure showing RUNX2/DAPI distribution in the surface of assembled tissue, spheroid-spheroid interface, and core of spheroids for strategy nos. 1 and 2. (M) BSP, COL1, ALP, RUNX2, and CDH2 gene expressions of 2D MSCs cultured in OM (control), 3D bioprinted tissues cultured in GM (control), and 3D bioprinted tissues cultured using strategy nos. 1 and 2 (n = 5; **P < 0.01 and ***P < 0.001).

Sodium alginate solution was made by dissolving 1% (w/v) sodium alginate (Sigma-Aldrich, UK) in deionized (DI) water. Calcium chloride solution was prepared by dissolving 4% (w/v) calcium chloride (CaCl2) (Sigma-Aldrich, St. Louis, MO) in DI water. For constructing fibrin scaffolds, fibrinogen (6 mg/ml) (Sigma-Aldrich) and thrombin (2.4 U/ml) (Sigma-Aldrich) were prepared for microvalve bioprinting. For bioprinting of electrocytes, agarose (A20070-100, Research Products International, IL) was dissolved in DI water to obtain a solution of 1% (w/v) agarose at 90C. COL I was extracted from rat tails according to a published protocol (54). GelMA was synthesized according to an established protocol (55). Detailed preparation methods of both materials can be found in the Supplementary Materials.

The mouse fibroblast cell line, 3T3, and the mouse mammary carcinoma line, 4T1, were obtained from the laboratory of A. Mastro, PSU (State College, PA). Culture media for 3T3 fibroblasts composed of Dulbeccos modified Eagles medium (DMEM) (Corning, Manassas, VA), supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Grand Island, NY) and 1% penicillin-streptomycin (Corning). 3T3 cells were used at passages 22 through 27. 4T1 cells were grown in RPMI (Corning), 10% FBS, 1% penicillin-streptomycin. Passages 7 through 12 were used for 4T1 cells. HUVECs were purchased from Lonza and cultured in MCDB 131 base media (Corning) supplemented with 10% FBS (Corning), 1% glutamine (Gibco, Life Technologies), 0.5% bovine brain extract (Lonza, Walkersville, MD), heparin (10 U/ml) (Sigma-Aldrich), endothelial cell growth supplement (3 mg/ml) (Sigma-Aldrich), and 1% penicillin-streptomycin (Corning). HUVECs were used at passages 3 through 8. HUVECs were also transduced in house with EF1 tdTomato lentivector (Vectalys, Toulouse, France) to ease cell visualization for fluorescence microscopy according to the manufacturers instructions. GFP+ HUVECs were purchased from Angio-Proteomie (cAP-0001GFP; Boston, MA) and were used at passages 2 through 5. HDFs, obtained from N. Zavazavas laboratory at The University of Iowa (Iowa City, IA), were cultured in DMEM supplemented with 10% FBS (Corning), 1% glutamine (Gibco), 1% sodium pyruvate (Gibco), and 1% penicillin-streptomycin (Corning). HDFs were used at passages 7 through 12. GFP+ HDFs were purchased from Angio-Proteomie (cAP-0008-adGFP; Boston, MA) and were used at passages 2 through 6. MSCs were obtained from Lonza (Walkersville, MD) and RoosterBio (Frederick, MD) and cultured in SU-005 RoosterBasal-MSC (RoosterBio). Passages 4 through 8 were used for MSCs. GFP+ MSCs were purchased from Cyagen, cultured in SU-005 RoosterBasal-MSC (RoosterBio), and used at passages 2 through 6.

All cells were maintained at 37C in a 5% CO2 humidified atmosphere. Cell culture medium was changed every 2 to 3 days. Subconfluent cultures were detached from the flasks using a 0.25% trypsin0.1% EDTA solution (Life Technologies) and split to maintain cell growth.

Adherent cultures of each cell type were detached from the culture vessels with 0.25% trypsin-EDTA (Life Technologies, Grand Island, NY) solution. Trypsin was neutralized with appropriate GM, and cells were counted by a hemocytometer. Each cell type was then diluted to a concentration of 2500, 5000, and 10,000 cells in 200 l of appropriate GM. The cell suspension (200 l) was then pipetted into a single well of a U-bottom 96-well microplate with a cell-repellent surface (Greiner Bio-One, Monroe, NC). For fabrication of MSC/HUVEC spheroids made of 50,000 cells, MSCs and HUVECs were combined at a ratio of 92:8. The microplates were then incubated at 37C in a 5% CO2 humidified atmosphere. Spheroid formation was monitored daily on an EVOS FL cell imaging system (Life Technologies). For fabrication of GFP+ HDF/MSC coculture spheroids, 5000 cells were used in total, and GFP+ HDFs and MSCs were cocultured in ratios of 2:1 and 1:1 for 1 day. During the fabrication and culture of HUVECs spheroids, EGM-2MV medium (Lonza) was used.

Field-emission SEM (FEI Nova NanoSEM 630) was used to investigate the surface topography of fabricated spheroids and dissociated electrocytes (see the Supplementary Materials for dissociation of electrocytes). Spheroids were harvested after 2 days of culture. Spheroids and electrocytes were fixed in 4% paraformaldehyde (Sigma-Aldrich) overnight; samples were then carefully washed in phosphate-buffered saline (PBS) and dehydrated using graded ethanol solutions (25 to 100%). To ensure complete removal of water, samples were further dried in a critical point dryer (CPD300, Leica EM, Wetzlar, Germany). On complete dehydration, they were sputter-coated with iridium (Leica) and imaged at an accelerating voltage of 3 to 5 keV.

A total of 1000 2-day cultured spheroids of each type (with ~2500 cells per spheroid) were collected and homogenized in 100 l of distilled water. Then, 100 l of cell homogenate was transferred to a 2-ml pressure-tight vial, added with 100 l of 12 M hydrochloric acid, and hydrolyzed at 120C for 3 hours. The total collagen amount per spheroid type was quantified using a hydroxyproline colorimetric assay kit (BioVision Inc., CA) according to the manufacturers instructions. Collagen amount expressed by each spheroid type was determined using a PowerWave X-340 spectrophotometer (BioTek, Winooski, VT) at 560 nm, and the results were normalized to the collagen amount expressed by HUVEC spheroids at day 2. Experiments were repeated four times.

Bioprinting of spheroids was used with a MakerBot Replicator 1 3D printer (MakerBot, NY). The extrusion head was removed, and a holder for a pipette and two microvalve heads was 3D-printed using an Ultimaker 2 (Ultimaker) 3D printer. To control the 3D motion stage, a smoothie board (Uberclock, OR) was integrated. The reader is referred to the Supplementary Materials for the details on the construction of the AAB platform.

For fabrication of support constructs, microvalves (INKX0517500A, Lee Company, Bashville, TN) with 250-m nozzles (INZA3100914K, Lee Company) were integrated on the bioprinter head. To operate microvalves, a control board (IECX0501350A, Lee Company) was used, which was controlled using Arduino Uno (Arduino, Italy). To cross-link sodium alginate, a portable ultrasonic humidifier (CZHD20, Comfort Zone, China) was used to generate the aerosol form of CaCl2. Details about the bioprinter setupincluding the computer aided design model (fig. S1D), block diagram (fig. S1E), and computer interface (fig. S20)can be found in the Supplementary Materials.

Spheroids were collected into a petri dish from U-bottom 96-well plates, and then, their surface tension was measured using a micropipette aspiration technique, as explained in our recent work (8). Aspirated spheroids were monitored via an STC-MC33USB monochromatic camera (Sentech, Japan) equipped with 1-61448 and 1-61449 adaptor tubes (Navitar, Rochester, NY).

Spheroids fixed in 4% paraformaldehyde (Sigma-Aldrich) and rinsed in Dulbeccos PBS (DPBS) were stained with NucBlue ReadyProbes reagent (Life Technologies) to visualize the cell nuclei (Fig. 3, A3 and A4); actin cytoskeletal fibers were stained with ActinGreen 488 ReadyProbes reagent according to the manufacturers instructions. Imaging and 3D reconstruction of a heterogeneous pyramid structure (Fig. 4A) was performed using a Zeiss confocal microscope (LSM 880, Carl Zeiss AG, Oberkochen, Germany) using a 5 lens. The 3D reconstruction was obtained using Zen blue software (Carl Zeiss AG). A diamond structure (Fig. 4D) was first imaged through Zeiss Axiozoom (Carl Zeiss AG, Oberkochen, Germany) to capture the entire 3D structure and then further imaged on a confocal microscope (Olympus FV1000, Olympus America Inc., Center Valley, PA) to closely image the DAPI (4,6-diamidino-2-phenylindole), F-actin, and CD31 staining.

Spheroids were removed from the U-bottom well plates and subjected to the bioprinting process. Spheroids directly taken from plates were used as a positive control group. Viability was assessed using a LIVE/DEAD viability assay kit (Life Technologies, Grand Island, NY). Briefly, spheroids were washed twice in DPBS and then placed in the dye solution consisting of 1 M calcein acetoxymethyl and 1.6 M ethidium homodimer-1 in PBS. Live cells were able to take up and retain the calcein dye, resulting in bright green fluorescence of their cytoplasm. The ethidium homodimer could only enter dead cells where it binds to nucleic acids, producing a bright red fluorescence. Spheroids were imaged at 20-m z-stack step size on the Olympus FV1000 confocal microscope with a 60-m aperture setting resulting in approximately five to seven images per spheroid. Each image was then analyzed using ImageJ software (National Institutes of Health, USA).

Spheroids made of 3T3 cells were collected from U-bottom 96-well plates and then washed with DPBS twice. CellTracker Orange CMTMR [5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethylrhodamine] (Thermo Fisher Scientific) and CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) (Thermo Fisher Scientific, MA) were used according to the manufacturers instructions. Spheroids were bioprinted with close proximity, and then, images were captured at 0, 24, 48, and 72 hours using EVOS FL Cell Imaging System. The contact length and contact angle of two spheroids were measured every 4 hours up to 24 hours.

Images of sprouting GFP+ and tdTomato+ HUVEC spheroids at day 7 were taken on the Zeiss Axiozoom microscope at a magnification of 20 to capture the spheroids bioprinted at various distances. Images of sprouts at days 2 and 5 were taken using the EVOS FL Cell Imaging System. Sprouting behavior of spheroids was analyzed using AngioTool (41). To obtain the cross-sectional view of the capillary-like structures formed by GFP+ and tdTomato+ HUVEC spheroids at day 7, samples were imaged using a 40 oil lens on the Olympus FV1000 confocal microscope. For the study with GFP+ HDF/MSC coculture and HUVEC spheroids, samples were imaged on the EVOS microscope using fluorescent (4) channels at days 2 and 5. Images of those samples on day 7 were taken using fluorescent (16 and 40) and phase (16) channels by the Axiozoom microscope.

To induce osteogenic differentiation, MSC/HUVEC spheroids were bioprinted and cultured in two different strategies in a custom culture media made of 92% osteogenic differentiation media (Cell Applications Inc., San Diego, CA) and 8% HUVEC culture media. To confirm the morphology of bioprinted tissues undergoing osteogenic differentiation, tissues were sectioned and stained with RUNX2, CD31, F-actin, and DAPI. Cross-sectioned samples were washed three times with DPBS, fixed in 4% paraformaldehyde for 60 min, permeabilized in 0.2% Triton X-100 for 30 min, and blocked with 2.5% normal goat serum (NGS) for 60 min at room temperature. To visualize osteogenic and endothelial-specific genes, the samples were incubated with mouse anti-RUNX2 primary antibody (1:100 in 2.5% NGS) and rabbit anti-CD31 primary antibody (1:100 in 2.5% NGS) for 60 min; washed three times with DPBS; and incubated with goat anti-mouse Alexa Fluor 488 secondary antibody (Molecular Probes; 1:250 in 2.5% NGS) to label RUNX2, goat anti-rabbit Alexa Fluor 647 secondary antibody (Molecular Probes; 1:250 in 2.5% NGS) to label CD31, Alexa Fluor 568 phalloidin (Molecular Probes; 1:1000 in 2.5% NGS) to label filamentous actin, and DAPI (1:1000 in 2.5% NGS) to visualize cell nuclei for 60 min. The stained samples were washed three times with DPBS and imaged by an Olympus FV10i-LIV Confocal Laser Scanning Microscope (Olympus America Inc.) and analyzed using ImageJ software. In addition to sectioned samples, bioprinted tissues were also stained, as a whole-mount sample, as explained above, and fluorescent images were taken on the Zeiss Axiozoom microscope.

To confirm the calcium deposition, cross-sectioned samples were fixed in 4% paraformaldehyde, washed three times with distilled water, and incubated with 2% Alizarin red S stain solution for 30 min at room temperature. Stained samples were washed three times with distilled water and imaged using the EVOS microscope.

To quantify the intensity of RUNX2 and CD31, areas of interest on confocal images were selected using ImageJ. Fifty regions of interest were determined at the surface of the assembled tissue, spheroid-spheroid interface, and core of spheroids on fluorescent images. Each box was used for quantification of the fluorescence intensity. The intensity of RUNX2 and CD31 was normalized by the intensity of DAPI. A representative heat map was generated for the RUNX2/DAPI intensity.

Real-time polymerase chain reaction (PCR) was performed to quantify the gene expression levels of BSP, COL1, ALP, RUNX2, and CDH2. The primers of the measured mRNA genes were as follows: BSP (forward, AAC GAA GAA AGC GAA GCA GAA and reverse, TCT GCC TCT GTG CTG TTG), COL1 (forward, ATG ACT ATG AGT ATG GGG AAG CA and reverse, TGG GTC CCT CTG TTA CAC TTT), ALP (forward, AGC TGA ACA GGA ACA ACG TGA and reverse, CTT CAT GGT GCC CGT GGT C), RUNX2 (forward, GGT TAA TCT CCG CAG GTC ACT and reverse, CAC TGT GCT GAA GAG GCT GTT), CDH2 (forward, GAG CAG TGA GCC TGC AGA TTT T and reverse, TGC TCA GAA GAG AGT GGA AAG CT), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (forward, ATG GGG AAG GTG AAG GTC G and reverse, GGG GTC ATT GAT GGC AAC AAT A). Real-time PCR was analyzed by using SsoFast EvaGreen Supermix (Bio-Rad, USA), and all results were normalized using GAPDH.

All data were presented as means SD and analyzed by Minitab 17.3 (Minitab Inc., State College, PA, USA) using one-way analysis of variance (ANOVA) to test for significance when comparing the data. Post hoc Tukeys multiple-comparison test was used to determine the individual differences among the groups. Differences were considered significant at *P < 0.05, **P < 0.01, and ***P < 0.001. For directionality analysis, t test was used to compare the results between AOI and Other (where differences were considered significant at *P < 0.05, **P < 0.01, and ***P < 0.001), and ANOVA (with Tukeys multiple comparison test) was used to compare the results among different groups (where differences were considered significant at #P < 0.05, ##P < 0.01, and ###P < 0.001). Repeated-measures ANOVA (with Tukeys multiple-comparison test) was conducted to compare the results among different days of same groups, and differences were considered significant at *P < 0.05, **P < 0.01, and ***P < 0.001.

See original here:
Aspiration-assisted bioprinting for precise positioning of biologics - Science Advances

Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible – Patheos

Stem cell research has been the subject of discussion and heated debate for many years. Much of the social and political drama surrounding stem cells is the result of misunderstanding what stem cells are, where they come from, and what they can do for those with injuries and diseases.

Working from a common set of facts is a great way to dispel controversy, however. Whether we fall into the pro-choice or pro-life camp, it is more than evident that supporting stem cell research, including the development of stem cell therapies, is very much a pro-life position to take.

Stem cells function essentially like raw materials for the body. Depending on instructions from the body (or researchers in laboratories), stem cells can become many other types of cells with specialized functions.

The daughters of stem cells either become new stem cells (self-renewal) or they become more specialized cells for use in specific areas of the body (differentiation). These specialized cells include brain cells, heart muscle cells, bone cells, blood cells and others.

There are several reasons why stem cells are the focus of some of the most important medical science research today:

This last avenue of medical research stem cell therapies is the most consequential as well as the most controversial, depending on your point of view. Understanding stem cell therapy and its divisiveness requires understanding where stem cells come from in medical research and why they have considerable palliative potential.

Stem cells come from one of these three sources:

Embryonic stem cells are the most controversial as well as the most important type of stem cells right now. Thanks to a low-information electorate and gross misinformation from within the government, embryonic stem cells remain mired in needless debate.

Despite the rhetoric, these cells arent harvested from slain newborns. Instead, they are carefully gathered from blastocysts. Blastocysts are three-to-five-day-old embryos comprised of around 150 cells. According to some religious-political arguments, blastocysts are potential human beings, and therefore deserve legal protection.

Embryonic stem cells are the most valuable in medical research because they are fully pluripotent, which means they are versatile enough to become any type of cell the body requires to heal or repair itself.

Adults have limited numbers of stem cells in a variety of bodily tissues, including fat and bone marrow. Unlike pluripotent embryonic stem cells, adult stem cells have more limits on the types of cells they can become.

However, medical researchers keep uncovering evidence that adult stem cells may be more pliable than they originally believed. There is reason to believe cells from adult bone marrow may eventually help patients overcome heart disease and neurological problems. However, adult stem cells are more likely than embryonic stem cells to show abnormalities and environment-induced damage, including cell replication errors and toxins.

The newest efforts in stem cell research involve using genetic manipulation to turn adult stem cells into more versatile embryonic variants. This could help side-step the thorny abortion controversy, but its also not clear at present whether these altered stem cells may bring unforeseen side-effects when used in humans.

More research is required to fully understand the medical potential of perinatal stem cells. However, some scientists believe they may in time become a viable replacement for other types of stem cells. Perinatal stem cells come from amniotic fluid and umbilical cord blood.

Using a standard amniocentesis, doctors can extract umbilical cord mesenchymal stem cells, hematopoietic stem cells, amniotic membrane and fluid stem cells, amniotic epithelial cells and others.

Among other things, stem cell therapy is the next step forward for organ transplants. Instead of waiting on a transplant waiting list, patients may soon be able to have new organs grown from their very own stem cells.

Bone marrow transplants are one of the best-known examples of stem cell therapy. This is where doctors take bone marrow cells and induce them to become heart muscle cells.

Stem cell-based therapies hold significant promise across a wide range of medical conditions and diseases. With the right approach, stem cells show the potential to:

As the FDA notes, there is a lot of hype surrounding stem cell therapy. Much of it is warranted, but some of it deserves caution.

According to the FDA, stem cells have the potential to treat diseases or conditions for which few treatments exist. The FDA has a thorough investigational process for new stem cell-based treatments. This includes Investigational New Drug Applications (IND) and conducting animal testing.

However, the FDA notes that not every medical entity submits an IND when they bring a new stem cell therapy to market. It is vital that patients seek out only FDA-reviewed stem cell therapies and learn all they can about the potential risks, which include reactions at the administration site and even the growth of tumors.

The FDA submitted a paper, Clarifying Stem-Cell Therapys Benefits and Risks, to the New England Journal of Medicine in 2017. Its goal is to help patients fully understand what theyre getting themselves into.

For now, a great deal more research is required before we begin deploying stem cell therapies on a larger scale. The only FDA-approved stem cell therapies on the market today involve treating cancer in bone marrow and blood. Some clinics claim their therapy delivers miracle-like cures for everything from sports injuries to muscular dystrophy, but there just isnt enough evidence yet to take them at face value.

Unfortunately, the religious and political climate makes this evidence difficult to achieve. In some parts of the United States, the hostility toward stem cell researchers and medical practitioners has reached dangerous new levels.

Republicans in Ohio and Georgia want to make it illegal for doctors to perform routine procedures on ectopic pregnancies. This condition is life-threatening for the mother and involves the removal of a nonviable embryo from the fallopian tube.

These laws wouldnt just outlaw ectopic pregnancy surgery in the name of potential human life. It would, in fact, require women to undergo a reimplantation procedure after the ectopic pregnancy is corrected by a physician. If this procedure was actually medically possible, it would be dangerous and unnecessary. Thankfully, it doesnt exist outside the nightmarish imaginations of some of the more extreme Christian lawmakers and Planned Parenthood demonstrators.

Acquiring embryonic stem cells from ectopic pregnancies would seem to be the least controversial way to go about it. Unfortunately, even that small step toward medical progress sees itself hampered by reactionary politics.

No matter how theyre acquired, however, the 150 or so cells in blastocysts are packed with medical potential. Its clear that further exploration down this road will unlock unprecedented scientific progress. It will also, almost certainly, save many times more potential life than even the most outlandish estimates of what the achievement will cost us to achieve. Abortions today are rarer and safer than ever, and the vast majority occur within eight weeks of conception.

The medical community is poised for a revolution here, using these and other nonviable embryos and blastocysts. But realizing that potential requires, among other things, that we collectively make peace with modern medicine and family planning.

Read more:
Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible - Patheos

Federal government investing nearly $7 million in stem cell research – inhalton.com

The federal government recently announced their intention to invest $6.9 million in stemcellresearch.

Stem cells are the building blocks of the body, and are responsible for growing and repairing tissue; they have the potential to treat a myriad of illnesses including heart disease--the leading cause of death inNorthAmerica.

Canada has been one of the leading countries when it comes to stem cell research, and Canadian researchers have brought stem cells from the lab into hospitals to savecountlesslives.

This funding will go towards nine translational projects and four clinical trials across the country aimed at providing new therapies and fostering continued growth in Canada's regenerativemedicinesector.

Two of the projects are being conducted by the Maisonneuve-Rosemont Hospital in Quebec; one trial involves testing a promising new protocol to make blood stem cell transplants available to more patients with severe leukemia, the other is a biotechnology partnership that is advancing a stem cell-based approach tovisionloss.

"When we invest in science, we invest in better, healthier lives for everyone," Navdeep Bains, Minister of Innovation, Science, and Industry, said in anewsrelease.

"Our government's support will help Canadian researchers further their ground-breaking work to tackle some of the most serious illnesses we face today. Congratulations to all of the recipients, and thank you for your work to keep Canada on the cutting edge of discovery and innovation,"hecontinued.

See the original post:
Federal government investing nearly $7 million in stem cell research - inhalton.com

Stem cell therapy used to treat severe cases – The Star Online

BEIJING: Chinese researchers are studying the use of stem cell technology in the treatment of people critically ill with the novel coronavirus disease (Covid-19), according to the Science and Technology Daily.

Four Covid-19 patients who received stem cell treatment while in a serious condition have been discharged from hospital after recovery, and the clinical trial of the therapy will be further expanded, Vice-Minister of Science and Technology Xu Nanping was quoted by the paper as saying.

Stem cells can self-renew or multiply while maintaining the potential to develop into other types of cells.

They can become cells of the blood, heart, lungs or other body parts.

Stem cells also have a strong secretory function, promoting the formation of new blood vessels, cell proliferation and differentiation and inhibiting inflammatory response, experts say.

Stem cell therapy has been used in the treatment of some infectious diseases and complications. For instance, it has been tried in treating H7N9 avian flu and showed good results.

According to the Ministry of Science and Technology, the Chinese Academy of Sciences has developed a new stem cell drug, CAStem, which has shown promising results in animal experiments.

The research team has applied for urgent assessment by the National Medical Products Administration.

Approvals by the ethics committee, and clinical observation and evaluation are in progress.

A research team from the fifth medical centre of the Chinese PLA General Hospital is cooperating with hospitals and institutions in Wuhan, the epicentre of the epidemic, and North Chinas Tianjin municipality to conduct clinical research on the safety and effectiveness of mesenchymal stem cell therapy in treating Covid-19 patients. China Daily/ANN

Read the original:
Stem cell therapy used to treat severe cases - The Star Online

NIH-funded i3 Center formed to advance cancer immunotherapy – Harvard Gazette

Steven Hodi Jr., the i3 Centers other PI, and director of Melanoma Center and the Center for Immuno-Oncology at Dana-Farber, and professor of medicine at Harvard Medical School (HMS), is leading the clinical cancer vaccine trial. He has been at the forefront of developing cancer immunotherapies using immune checkpoint inhibitors, a class of drugs able to re-activate tumor-destroying T cells that are muted in the tumor microenvironment. The funding for this center provides a unique opportunity to unite key investigators for translating fundamental advancements in immunology and biomedical engineering into highly synergistic approaches to improve the treatments for cancer patients, said Hod

Using both in vivo and ex vivo biomaterials-based approaches, the i3 Center aims to boost tumor-specific activities of cytotoxic T cells, by boosting different stages of the normal process by which T cells develop, and acquire anti-cancer activity. T cells normal development starts in the bone marrow where hematopoietic stem cells generate T cell progenitor cells. These migrate to the thymus to differentiate into nave T cells, which then travel further to lymph nodes. There, they encounter cancer-derived antigens presented to them by specialized antigen-presenting cells (APCs) that can activate T cells to recognize and eliminate cancer cells.

In relation to adoptive T cell therapies in which T cells are given to patients to fight their cancers, one team at the i3 Center will be led by Dana-Farber researchers Catherine J. Wu and Jerome Ritz, who along with Mooney, will develop and test biomaterials that can better mimic normal APCs in activating and directing the function of patient-derived T cells outside the human body, prior to their transplantation. Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies, and Ritz is executive director of the Connell and OReilly Families Cell Manipulation Core Facility at Dana-Farber.

We need to make efforts to enhance the ability of theimmune systemto recognizetumor cells. One directionmylaboratoryis taking makes use of innovative biomaterialsto help us to efficiently expandpolyclonaltumor-specificfunctionally-effectiveT cellsex vivoin a way that can be readily translated to theclinical setting. In our studies, we are currently focusing on melanoma and acute myeloid leukemia, said Wu, whose research interests include understanding the basis of effective human anti-tumor responses, including the identification and targeting of the tumor-specific antigens.

A second project explores the use of DNA origami, biocompatible nanostructures composed of DNA, to create cancer vaccines. DNA origami could provide significant advantages in presenting tumor-specific antigens and immune-enhancing adjuvants to APCs because the concentrations, ratios, and geometries of all components can be modulated with nano-scale precision to determine configurations that are more effective than other vaccination strategies. The project will be run by Wyss Institute Core Faculty member William Shih, Derin Keskin, lead immunologist at Dana-Farbers Translational Immunogenomics Lab, and Mooney.

In a third project, David Scadden, professor at Harvards Department of Stem Cell and Regenerative Biology, will collaborate with Mooney to build on their previous work. They will engineer biomaterials that recreate key features of the normal hematopoietic stem cell niche in the bone marrow. Such implantable biomaterials could help rapidly amplify T cell progenitor cells, and enhance T cell-mediated anti-cancer immunity. Scadden also is the Gerald and Darlene Jordan Professor of Medicine at Harvard University, and co-director of the Harvard Stem Cell Institute.

The i3 Centers investigators anticipate that it will stimulate additional cross-disciplinary concepts and research, due to the culture of continuous interactions, sharing of findings, data and samples between all investigators, as well strong biostatistical expertise provided by Donna Neuberg, a senior biostatistician broadly involved with exploring immune-modulating cancer interventions at the Dana-Farber.

This new i3 Center for cancer immunotherapy innovation really embodies how the Wyss Institute with its unparalleled capabilities in bioengineering and serving as a site for multidisciplinary collaboration, and can liaise with clinicians and researchers at our collaborating institutions to confront major medical problems and bring about transformative change, said Wyss Founding Director Donald Ingber. He is also theJudah Folkman Professor of Vascular Biologyat HMS and the Vascular Biology Program at Boston Childrens Hospital, and Professor of Bioengineering at SEAS.

Continued here:
NIH-funded i3 Center formed to advance cancer immunotherapy - Harvard Gazette